HCV Tier 1 – The Approach to the Patient with HCV Infection (Monograph)

Learning Objectives

 

  • Provide optimal quality of care based on established quality indicators for HCV patients.
  • Implement HCV treatment to the fullest extent, ensuring all gaps in treatment are adequately addressed. 
  • Describe DAA drug therapies so that they may be administered and monitored in HCV patients, in accordance with practice guidelines.
  • Implement HCV treatment to the fullest extent, ensuring all gaps in treatment are adequately addressed. 
  • List three side effects of DAA agents.
  • Identify the timeframe for each side effect that may occur.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)
  • 0.50 Attendance
Registration Opens: 
01/30/2014
Registration Expires: 
01/29/2015

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)
  • 0.50 Attendance
Please login or register to take this course.